A state of art review on vardenafil in men with erectile dysfunction and associated underlying diseases

Bibliography

• Feldman HA, Goldstein I, Hatzichristou DG, Impotence andits medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61
   PubMed Web of Science ®Google Scholar
• Lewis RW, Fugl-Meyer KS, Bosch R, Epidemiology/risk factors of sexual dysfunction. J Sex Med 2004;1(1):35-9
   Google Scholar
• Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States. Prevalence and predictors. JAMA 1999;281:537-44
   PubMed Web of Science ®Google Scholar
• Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002;56:453-9
   PubMed Web of Science ®Google Scholar
• Goldstein I, Lue TF, Padma-Nathan H, Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338:1397-404
   PubMed Web of Science ®Google Scholar
• Palit V, Eardley I. An update of new oral PDE5 inhibitors for the treatment of erectile dysfunction. Nat Rev Urol 2010;7:603-9
   PubMed Web of Science ®Google Scholar
• Rosen RC, Fisher WA, Eardley I, The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004;20:607-17
   PubMed Web of Science ®Google Scholar
• Jackson G, Rosen RC, Kloner RA, Kostis JB. The Second Princeton Consensus on erectile dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med 2006;3:28-36
   PubMed Web of Science ®Google Scholar
• Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 2003;89:251-3
   PubMed Web of Science ®Google Scholar
• Montorsi P, Ravagnani PM, Galli S, Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J 2006;27:2632-9
   PubMed Web of Science ®Google Scholar
• Thompson IM, Tangen CM, Goodman PJ, Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005;294:2996-3002
   PubMed Web of Science ®Google Scholar
• Montorsi F, Briganti A, Salonia A, Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003;44:360-5
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet P, Shaw J. Metabolic syndrome- a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 2006;23:469-80
   PubMed Web of Science ®Google Scholar
• Eardley I, Donatucci C, Corbin J, Pharmacotherapy for erectile dysfunction. J Sex Med 2010;7(1 Pt 2):524-40
   PubMed Web of Science ®Google Scholar
• Gittelman M, McMahon CG, Rodrigues-Rivera JA, The POTENT II randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. Int J Clin Pract 2010;64:594-603
   PubMed Web of Science ®Google Scholar
• Sperling H, Debruyne F, Boermans A, The POTENT I randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. J Sex Med 2010;7-1497-507
   PubMed Web of Science ®Google Scholar
• Cheng E. Real-Life safety and efficacy of vardenafil in the treatment of erectile dysfunction- results from 30,010 U.S. patients. J Sex Med 2007;4:432-9
   PubMedGoogle Scholar
• Ziegler D, Merfort F, van Ahlen H, Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med 2006;3:883-91
   PubMed Web of Science ®Google Scholar
• Van Ahlen H, Wahle K, Kupper W, Safety and efficacy of vardenafil, a selective phosphodiesterase-5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multihypertensives. J Sex Med 2005;2:856-64
   PubMed Web of Science ®Google Scholar
• Thadani U, Smith W, Nash S, The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002;40:2006-12
   PubMed Web of Science ®Google Scholar
• Montague DK, Jarow JP, Broderick GA, Chapter 1: the management of erectile dysfunction: an AUA update. J Urol 2005;174:230-9
   PubMed Web of Science ®Google Scholar
• Hatzichristou D, Amar E, Eardley I, Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010;57(5):804-14
   Google Scholar
• Tsertsvadze A, Fink HA, Yazdi F, Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and metanalysis. Ann Int Med 2009;151(9):650-61
   PubMed Web of Science ®Google Scholar
• Hatzimouratidis K, Burnett AL, Hatzichristou D, Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rational and clinical application. Eur Urol 2009;55(2):334-47
   Google Scholar
• Candy B, Jones L, Williams R, Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatment of prostate cancer: findings from a Cochrane systematic review. BJU Int 2008;102(4):426-31
   Google Scholar
• Moore RA, Derry S, McQuay HJ. Indirect comparison of interventions using published randomised trials: systematic review of PDE 5 inhibitors for erectile dysfunction. BMC Urol 2005;14:5-18
   Google Scholar
• Valiquette L, Montorsi F, Auerbach S, Vardenafil Study Group. First-dose success with vardenafil in men with erectile dysfunction and associated comorbidities: RELY-I. Int J Clin Pract 2006;60(11):1378-85
   Google Scholar
• Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006;113:1888-904
   PubMed Web of Science ®Google Scholar
• Rhoden EL, Ribeiro EP, Riedner CE, Glycosylated haemoglobin levels and the severity of erectile function in diabetic men. BJU Int 2005;95:615-17
   PubMed Web of Science ®Google Scholar
• Goldstein I, Young JM, Fischer J, Vardenafil, a new phosphodiesterase type 5 inhibitors, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind, placebo-controlled fixed-dosed study. Diabetes Care 2003;26:777-83
   PubMed Web of Science ®Google Scholar
• Ishii N, Nagano K, Fujikawa K, Avrdenafil 20mg demonstrated superior efficacy to 10mg in Japanese men with diabetes mellitus suffering from erectile dysfunction. Int J Urol 2006;13:1066-72
   PubMed Web of Science ®Google Scholar
• Shabsigh R, Duval S, Shah M, Efficacy of vardenafil for the treatment of erectile dysfunction in men with hypertension: a meta-analysis of clinical trial data. Curr Med Res Opin 2007;23:2453-60
   PubMed Web of Science ®Google Scholar
• Reffelman T, Kloner R. Sexual function in hypertensive patients receiving treatment. Vasc Heath Risk Manag 2006;2(4):447-55
   Google Scholar
• Ferrario CM, Levy P. Sexual function in patients with hypertension: implications for therapy. J Clin Hypertens 2002;4:424-32
   PubMedGoogle Scholar
• Park K, Shin JW, Oh JK, restoration of erectile capacity in normotensive aged rats by modulation of angiotensin receptor type 1. J Androl 2005;26:123-8
   PubMedGoogle Scholar
• Data on file. US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee: Levitra tablets. Available from: http://www.fda.gov.ohrms/ac/03/slides/3956S1_03_Bayer_files/frame.htm. [Accessed 5 September 2003]
   Google Scholar
• Auerbach S, Gittelman M, Mazzu A, Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hypertrophy. Urology 2004;64(5):998-1003; discussion 1003-4
   Google Scholar
• Kloner RA. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol 2005;96(12B):42M-6M
   Google Scholar
• Saltzman EA, Guay AT, Jacobson J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. J Urol 2004;172:255-8
   PubMed Web of Science ®Google Scholar
• Miner MM, Barnes A, Janning S. Efficacy of phosphodiesterase type 5 inhibitor treatment in men with erectile dysfunction and dyslipidemia: a post hoc analysis of the vardenafil statin study. J Sex Med 2010;7(5):1937-47
   Google Scholar
• Ferrini MG, Davila HH, Kovanecz I, Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urol 2006;68:429-35
   PubMed Web of Science ®Google Scholar
• Montorsi F, Brock B, Lee J, Effect of nightly versus on-demand vardenafil on recover of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008;54(4):924-31
   Google Scholar
• Thompson IM, Tangen CM, Goodman PK, Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005;294:2996-3002
   PubMed Web of Science ®Google Scholar
• Chang LL, Ma M, Allmen H, Co-possession of phoshodiesterase-5 inhibitors (PDE5-I) with nitrates. Curr Med Res Opin. 2010;26(6):1451-9
   Google Scholar
• Cheitlin MD, Hutter AM Jr, Brindis RG, ACC/AHA expert consensus document use of sildenafil (Viagra) in patients with cardiovascular disease: American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999;33:273-82
   PubMed Web of Science ®Google Scholar
• Kloner RA, Hutter AM, Emmick JT, Time course of the interaction between tadalafil and nitrates. J Am Cardiol 2003;42:1855-60
   Web of Science ®Google Scholar
• Oliver JJ, Bell K, Leekie SM, Webb DJ. Interaction between gyceryl trinitrate and sildenafil citrate (Viagra) may last less than four hours. Int J Impot Res 2002;14(s3):S22
   Google Scholar
• Park JW, Leithauser B, Jung F. Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition. Clin Hemorheol Microcirc 2008;39(1-4):323-8
   Google Scholar
• Tolra JR, Campafia JM, Ciutat LF, Miranda EF. Prospective, randomized, open-label, fixed dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J Sex Med 2006;3:901-9
   PubMed Web of Science ®Google Scholar
• Jannini ED, Isidori AM, Gravina GL, The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. J Sex Med 2009;6(9):2547-60
   Google Scholar
• Rubio-Aurioles E, Porst H, Eardley I, Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. J Sex Med 2006;3(6):1037-49
   Google Scholar
• Carcon CC, Hatzichristou DG, Carrier S, Patient response with vardenafil in sildenafil non-responders (PROVEN) study group. Erectile response with vardenafil in sildenafil nonresponders: multicentre, double-blind, 12 week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. BJU Int 2004;94:1301-9
   Google Scholar
• Hatzichristou DG, Aliotta P, Auerbach S, Patient response with vardenafil in sildenafil non-responders (PROVEN) study group. Erectile response to vardenafil in men with a history of nonresponse to sildenafil: a time-from-dosing descrption analysis. Clin Ther 2005;27(9):1452-61
   Google Scholar
• Hatzimouratidis K, Moysidie K, Bekos A, Treatment strategy for “non-responders” to tadalafil and vardenafil: a real-life study. Eur Urol 2006;50(1): 126-32; discussion 132-3
   Google Scholar